info@bronchiectasis-rti.org
Subscribe to our newsletter
Linkedin-in X-twitter
European Bronchiectasis Workshop
Respiratory Tract Infections
Register now

GENERAL SUBMISSION RULES: ABSTRACTS FOR ORAL PRESENTATION, POSTER PRESENTATION & RISING STARS

PURPOSE

You are invited to submit an abstract of original research relevant to the conference topics for consideration as:

Oral Presentation

Poster Presentation

Rising Star

TOPICS

The main topic areas have been determined and reflect key questions to be discussed:

EBROW

AI Tools
Bronchiectasis pipeline
CFTR Dysfunctions
Clinical Trials
Clinical Management of bronchiectasis
Exacerbations
Remote monitoring

EBROW + RTI

Bronchiectasis
Fungal disease
Impossible pathogens
NTM - Nontuberculous mycobacteria

RTI

Covid
Emerging antiviral approach
Pneumonia
Rapid Diagnostics
Tuberculosis
RSV

GENERAL INFORMATION

The deadline for abstract submissions is Monday 16 November 2026. Abstract submissions will only be accepted via the online platform.

  • Abstracts must be submitted on or before the above-mentioned deadline, the organisers reserve the right to reject any abstract not following the required format.
  • Changes on abstracts are possible until the deadline by re-entering the online submission.
  • The abstract must be written in English. (If English is not your first language, please have it reviewed. The abstract must not contain any spelling, grammatical or scientific errors).
  • No corrections are possible after the submission deadline. The abstract will be reproduced exactly as submitted.
  • All the communications concerning the abstract will be sent to the submitter who will be responsible for informing the other authors of the status of the abstract.
  • For each abstract a presenting author has to be identified. For any change in the presenter’s name, please make sure to inform the Organising Secretariat info@bronchiectasis-rti.org
  • The presenting author must accept full responsibility for the content, submission and presentation of the abstract, and retain full copyright of their abstract and presentation.
  • By submitting an abstract, authors grant the conference permission to publish, or submit for publication, their abstract and any accompanying materials, including images, graphs and biographies.
  • The submitted work must not have been published as a full paper in a journal by the time of the meeting, or have appeared in print elsewhere (except in abstract form) prior to the meeting.
  • Presenting authors should be registered participants.

GUIDELINES FOR SUBMISSION

  • Structured abstracts are mandatory, clearly stating: Background/Aims, Methods, Results and Conclusions
  • Abstracts should be written in English and the complete abstract must not exceed the box space (500 words). Abstracts can contain formulas, pictures or graphs
  • We recommend that you prepare your text in a word processing programme (e.g. Microsoft Word) and then copy-paste the final text into the online abstract submission form
  • It is possible to submit more than one abstract.

  • A submitted abstract can have a maximum of one presenting author.
  • A submitted abstract can be edited online until the given deadline, Monday 16 November 2026
  • Conflict of Interest/Disclosure: Abstracts must include an acknowledgement of any commercial funding sources. Authors should declare all commercial interests
  • All studies must have been approved by institutional committees on ethics of experimental and human investigations

THE ABSTRACT SUBMISSION STEP BY STEP

To submit your abstract online, please follow these instructions:

  • Enter the online system and fill your personal details (if you do not have an existing profile)
  • Select the appropriate category from the listInsert the author’s and co-author’s name/sInsert affiliations for each author and associate
  • Make sure that you identify the Presenter among the existing authorsInsert the abstract Title
  • Insert the body copy (this must be submitted in the required format)
  • Upload the Competing Interest Disclosures for each author (If there are no competing interests, it should be stated in the form)
  • For ‘Rising Star’ (only): Upload a full academic curriculum including publications and / or poster presentations made in the past

If you have any questions regarding abstracts, please write to info@bronchiectasis-rti.org

SUBMISSION DEADLINE: Monday 16 November 2026

Scientific Committee member 4
Member · EBROW Scientific Committee

Michal Shteinberg

Carmel Medical Center and the Technion, Haifa

Michal Shteinberg is heading the bronchiectasis and adult CF service in the Pulmonology institute and CF center, Carmel medical center, Haifa, Israel. She is a Clinical Assistant Professor in the Faculty of medicine at the Technion, Israel Institute of Technology. Her main research interests are bronchiectasis and its overlap with other airway diseases, and adult CF.

Scientific Committee member 5
Member · EBROW Scientific Committee

Oriol Sibila

Hospital Clínic de Barcelona, Spain

Head of the Pulmonology Service at Hospital Clínic de Barcelona and accredited researcher in the IDIBAPS group Inflammation and Repair in Respiratory Diseases. His work focuses on airway infection, inflammation and bronchiectasis, including frequent-exacerbator phenotypes in the EMBARC registry.

He coordinates educational programmes on bronchiectasis at Hospital Clínic and publishes widely on mucins, inhaled therapies and treatable traits in chronic airway disease.

Scientific Committee member 2
Member · EBROW Scientific Committee

Natalie Lorent

University Hospital Leuven, Belgium

Natalie Lorent works as a consultant in Respiratory Medicine/Clinical Infectiology at the University Hospital Leuven where since 2015 she coordinates the care for adults with respiratory infections, bronchiectasis (CF and non-CF) and primary ciliary dyskinesia. She is involved in clinical and translational research in bronchiectasis and mycobacterial infections.

She is founder and president of the national NTM Consilium, a clinical advisory board and basis of a national registry; she chairs the European NTM research network (NTMnet) and the Belgian MDRTB expert group. She has been involved in EMBARC since the start. Natalie is also assistant professor at KU Leuven.

Scientific Committee member 3
Member · EBROW Scientific Committee

Felix C. Ringshausen

Hannover Medical School (MHH) and German Center for Lung Research

Felix C. Ringshausen is a board-certified physician for respiratory medicine and infectious diseases and head of the Adult Bronchiectasis and Cystic Fibrosis Service at the Hannover Medical School, Germany. In addition, he is principal investigator of the German Center for Lung Research (DZL).

His research interests are focused on European multidisciplinary networks and multicenter initiatives in order to promote clinically orientated research and improve patient care in the field of rare, neglected and under-researched aspects of respiratory infections like bronchiectasis, nontuberculous mycobacteria, respiratory viruses and adult cystic fibrosis.

Scientific Committee member 1
Member · EBROW Scientific Committee

Stefano Aliberti

Humanitas University, Italy

Professor of Respiratory Medicine, Humanitas University, Milan, Italy. Consultant, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan.

Co-chair of the European Bronchiectasis Network (EMBARC). Chair of IRIDE, the Italian Registry of adult bronchiectasis. Chair of the Italian Registry on Non-Tuberculous Mycobacteria (IRENE).

Michael Loebinger
Co-chair · EBROW Organising Committee

Michael Loebinger

Royal Brompton Hospital · Imperial College London

Professor Michael Loebinger is Professor of Practice at Imperial College London and Director of the Lung Division and Deputy Medical Director at Royal Brompton Hospital. He co-chaired the British Thoracic Society bronchiectasis guidelines and co-wrote the BTS Non-Tuberculous Mycobacteria and European Respiratory Society bronchiectasis guidelines.

He is a founding member of the UK and European clinical and research bronchiectasis and NTM networks and has authored over 200 publications. He has helped design and lead multiple global clinical trials in bronchiectasis and NTM and was chief investigator for the first mRNA trials in primary ciliary dyskinesia.

Charles Haworth
Co-chair · EBROW Organising Committee

Charles Haworth

Royal Papworth Hospital, Cambridge, United Kingdom

Charles Haworth is a Respiratory Consultant working within the Cambridge Centre for Lung Infection at Royal Papworth Hospital where he specialises in treating adults with bronchiectasis, non-tuberculous mycobacterial (NTM) infections and cystic fibrosis.

He co-authored the British Thoracic Society Bronchiectasis clinical guidelines published in 2017 and the European Respiratory Society Bronchiectasis clinical guidelines published in 2019.

He was also senior author of the International Cystic Fibrosis NTM guidelines published in 2015 and first author of the British Thoracic Society NTM guidelines published in 2017.

From 2018 to 2021, he was a founding and executive committee member of the UK Cystic Fibrosis Medical Association.

In June 2024 he was invited to join the Board of the European Cystic Fibrosis Society.

James D. Chalmers
Co-chair · EBROW Organising Committee

James D. Chalmers

University of Oxford, United Kingdom

Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology, University of Oxford.

Chief Editor of the European Respiratory Journal.

Chair of the European Bronchiectasis Network (EMBARC).

Chair of the Standards of Care Committee of the British Thoracic Society.